Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 November 2006Website:
http://www.catalystpharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:53:51 GMTDividend
Analysts recommendations
Institutional Ownership
CPRX Latest News
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.
Catalyst (CPRX) has the perfect mix of factors for a potential earnings outperformance in its upcoming report. Be ready with the important projections.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being held in Miami on March 12-14, 2024.
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.22 per share a year ago.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD) who are treated with AGAMREE® (vamorolone) at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET
The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.
Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.
What type of business is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
What sector is Catalyst Pharmaceuticals in?
Catalyst Pharmaceuticals is in the Healthcare sector
What industry is Catalyst Pharmaceuticals in?
Catalyst Pharmaceuticals is in the Biotechnology industry
What country is Catalyst Pharmaceuticals from?
Catalyst Pharmaceuticals is headquartered in United States
When did Catalyst Pharmaceuticals go public?
Catalyst Pharmaceuticals initial public offering (IPO) was on 08 November 2006
What is Catalyst Pharmaceuticals website?
https://www.catalystpharma.com
Is Catalyst Pharmaceuticals in the S&P 500?
No, Catalyst Pharmaceuticals is not included in the S&P 500 index
Is Catalyst Pharmaceuticals in the NASDAQ 100?
No, Catalyst Pharmaceuticals is not included in the NASDAQ 100 index
Is Catalyst Pharmaceuticals in the Dow Jones?
No, Catalyst Pharmaceuticals is not included in the Dow Jones index
When does Catalyst Pharmaceuticals report earnings?
The next expected earnings date for Catalyst Pharmaceuticals is 09 August 2024